Malignant neoplasms (malign tumors) called T-cell Lymphoma, peripherical, T zone Lymphoma.
Conditions
Interventions
An analytical, transversal, observational study where it is expected to enroll about 500 patients. Demographic data, diagnosis, treatment, response every 6 months, whether relapse or progression, re-t
Other
Sponsors
Hospital Samaritano de Sao Paulo Ltda
GEMOH- Grupo de estudos multicentricos em onco-hematologia
Hemocentro-Unicamp (Centro de Hematologia e Hemoterapia da Universidade Estadual de Campinas)
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Date of diagnosis from January, 2015, Newly diagnosed patients with T-cell or T/NK cell peripherical lymphomas; tissue biopsies adequate for diagnosis and classification, all available for centralizes review; clinical data including baseline information on disease localization and laboratory parameters at staging, features on treatment adopted and assurance of follow up updating for at least 5 years are requested. Besides that, dated and signed consent form.
Exclusion criteria
Exclusion criteria: If diagnosis of Blastic NK-cell leukemia/lymphoma; Aggressive NK-cell leukemia; T-cell large granular lymphocytic leukemia; T-cell large granular lymphocytic proliferation; NK-cell large granular lymphocytic proliferation; T-cell prolymphocytic leukemia; Precursor T-cell lymphoblastic leukemia/lymphoma; mycosis fungoides; sézary syndrome; primary cutaneous ALCL.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected Outcome 1. the 5-year overall survival. The overall survival (OS) will be based on date of diagnosis until follow-up date or date of death, in months. The event will be the death by any cause, whereas the othes will be censured in the last contact date. The Kaplan-Meier method and the Log-Rank test will be applied to check if there are differences among several stratification, such as, 5 Brazilian regions and different type of T-Cell lymphomas. This analyses will be done twice a year. | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected outcome 2. Event free survival (EFS). The events for EFS will be the relapse, progression, toxicity caused by treatment and death by any cause. Kaplan-Meier method and the Log-Rank test will be applied to check if there are differences among several stratifications. This analyses will be done twice a year.;Expected outcome 3. Progression free survival (PFS). The events for PFS will be progression of disease and death caused by lymphoma. Kaplan-Meier method and the Log-Rank test will be applied to check if there are differences among several stratifications. This analyses will be done twice a year. ;Expected outcome 4. Rate of complete or partial response. Based on total number of patients will be calculated how many patients will get complete remission after first line treament. This analyses will be done twice a year. | — |
Countries
Brazil
Contacts
Public ContactMarcia;Nicete Delamain;Romano
Hemocentro-Unicamp (Centro de Hematologia e Hemoterapia da Universidade Estadual de Campinas);Hemocentro-Unicamp (Centro de Hematologia e Hemoterapia da Universidade Estadual de Campinas)
Outcome results
None listed